Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1475-2840
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure ; volume:19 ; number:1 ; day:30 ; month:9 ; year:2020 ; pages:1-16 ; date:12.2020
Cardiovascular diabetology ; 19, Heft 1 (30.9.2020), 1-16, 12.2020

Urheber
Sayour, Alex Ali
Oláh, Attila
Ruppert, Mihály
Barta, Bálint András
Horváth, Eszter Mária
Benke, Kálmán
Pólos, Miklós
Hartyánszky, István
Merkely, Béla
Radovits, Tamás
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12933-020-01141-1
URN
urn:nbn:de:101:1-2020111514380943520040
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:37 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Sayour, Alex Ali
  • Oláh, Attila
  • Ruppert, Mihály
  • Barta, Bálint András
  • Horváth, Eszter Mária
  • Benke, Kálmán
  • Pólos, Miklós
  • Hartyánszky, István
  • Merkely, Béla
  • Radovits, Tamás
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Verbundene Objekte